Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
12 nov. 2024 08h00 HE
|
Compass Therapeutics
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first...
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
05 nov. 2024 16h01 HE
|
MacroGenics, Inc.
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed...
Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
04 nov. 2024 07h30 HE
|
Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
MacroGenics Announces Leadership Transition
30 oct. 2024 07h30 HE
|
MacroGenics, Inc.
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:...
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
12 août 2024 08h00 HE
|
Compass Therapeutics
Compass Therapeutics announces 2nd quarter results and provides clinical results update
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
06 août 2024 08h00 HE
|
Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
[Latest] Global Bispecific Antibodies Market Size/Share Worth USD 53.8 Billion by 2033 at a 24.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
04 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 04, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Bispecific Antibodies Market Size, Trends and Insights By Application (Cancer...
Tobemstomig Clinical Trials Bispecific Antibodies Market Clinical Trials Drug Sales Market Forecast 2029
17 mars 2024 13h28 HE
|
KuicK Research
Delhi, March 17, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 BillionApproved Bispecific...
Plamotamab Clinical Trials Global Bispecific Antibodies Market Drug Sales Report 2029
17 mars 2024 13h23 HE
|
KuicK Research
Delhi, March 17, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 BillionApproved Bispecific...
Pidilizumab Clinical Trials Bispecific Antibodies Market Report 2029
17 mars 2024 13h09 HE
|
KuicK Research
Delhi, March 17, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 BillionApproved Bispecific...